Literature DB >> 26436948

Development and Characterization of Nanoembedded Microparticles for Pulmonary Delivery of Antitubercular Drugs against Experimental Tuberculosis.

Amit Kumar Goyal1, Tarun Garg1,2, Goutam Rath1,2, Umesh Datta Gupta3, Pushpa Gupta3.   

Abstract

The foremost objective of the present research study was to develop and evaluate the potential of rifampicin (RIF) and isoniazid (INH) loaded spray dried nanoembedded microparticles against experimental tuberculosis (TB). In this study, RIF-INH loaded various formulations (chitosan, guar gum, mannan, and guar gum coated chitosan) were prepared by spray drying and characterized on the basis of in vitro as well as in vivo studies. Results showed that guar gum spray dried particles showed uniform size distribution with smooth surface as compare to mannan formulations. Guar gum batches exhibited excellent flow ability attributed to their optimum moisture content and uniform size distribution. The drug release showed the biphasic pattern of release, i.e., initial burst followed by a sustained release pattern. The preferential uptake of guar gum coated formulations suggested the presence and selective uptake capability of mannose moiety to the specific cell surface of macrophages. In vivo lung distribution study showed that guar gum coated chitosan (GCNP) batches demonstrated prolonged residence at the target site and thereby improve the therapeutic utility of drug with a significant reduction in systemic toxicity. Optimized drug loaded GCNP formulation has resulted in almost 5-fold reduction of the number of bacilli as compared to control group. Histopathology study also demonstrated that none of the treated groups show any evidence of lung tissue abnormality. Hence, GCNPs could be a promising carrier for selective delivery of antitubercular drugs to alveolar macrophages with the interception of minimal side effects, for efficient management of TB.

Entities:  

Keywords:  alveolar macrophages; challenge studies; guar gum coated chitosan; nanoembedded microparticles; pulmonary drug delivery; tuberculosis

Mesh:

Substances:

Year:  2015        PMID: 26436948     DOI: 10.1021/acs.molpharmaceut.5b00016

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  4 in total

Review 1.  Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases.

Authors:  Caleb F Anderson; Maria E Grimmett; Christopher J Domalewski; Honggang Cui
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-10-10

2.  Hierarchical pulmonary target nanoparticles via inhaled administration for anticancer drug delivery.

Authors:  Rui Chen; Liu Xu; Qin Fan; Man Li; Jingjing Wang; Li Wu; Weidong Li; Jinao Duan; Zhipeng Chen
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

3.  Preparation and characterization of beta-glucan particles containing a payload of nanoembedded rifabutin for enhanced targeted delivery to macrophages.

Authors:  Tarun K Upadhyay; Nida Fatima; Deepak Sharma; V Saravanakumar; Rolee Sharma
Journal:  EXCLI J       Date:  2017-03-07       Impact factor: 4.068

Review 4.  Chitosan Nanoparticle-Based System: A New Insight into the Promising Controlled Release System for Lung Cancer Treatment.

Authors:  Cha Yee Kuen; Mas Jaffri Masarudin
Journal:  Molecules       Date:  2022-01-12       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.